The Tech Tribune, the journalistic arm of Crunchbase, recently selected Hesperos as one of the top 10 technology startups in Orlando. We are proud to be listed among the best companies in the City Beautiful. Award recipients cover a wide range of industries and were selected based on several factors including revenue potential and leadership … Read more
Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful to have funding to support research in an area that represents such a large and growing need,” said Dr. … Read more
HUMAN-ON-A-CHIP PREDICTS IN VIVO RESULTS BASED ON IN VITRO MODEL FOR THE FIRST TIME Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known … Read more
Dr. Shuler’s “UniChip enables long-term recirculating unidirectional perfusion with gravity-driven flow for microphysiological systems” has been selected by the handling Editor as one of the top 10% of papers published in Lab on a Chip. This selection is based on the exceptionally positive referee reports that the manuscript received during peer review, along with the Editor’s … Read more
(ORLANDO, Fla.) Hesperos, Inc. has announced that it is among the first round of finalists for the 2018 Florida Companies to Watch honor, recently announced by GrowFL. The awards event – now in its eighth year – honors 50 select second-stage companies from throughout the state for developing valuable products and services, creating quality jobs, enriching communities, … Read more
ORLANDO, FLA – April 25, 2018 — Hesperos, Inc. has increased its pioneering human-on-a-chip drug testing capabilities by adding a new in vitro, human-human neuromuscular model to its patented multi-organ microfluidic device systems. Abnormal function of the neuromuscular junction is associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, and … Read more
Getting drugs past the neuroprotective blood-brain barrier (BBB) has been a perplexing problem and formidable challenge for researchers and pharmaceutical companies alike. Hesperos’s creation of a microfluidic model capable of mimicking in vivo characteristics of the blood-brain barrier for prolonged periods was therefore widely welcomed, and recently earned CEO Michael L. Shuler recognition from the American … Read more
The challenge: Build microfluidic devices that can keep cells alive in a setting that mimics specific organs or tissues, and incorporate biosensors to measure the cells’ physiology. The goal: Mimic diseases and test drug responses that traditional 2D culture systems and animal models have been unable to predict, filling a critical gap in drug development … Read more
For the second year in a row, SLAS Technology has chosen the article “TEER Measurement Techniques for In Vitro Barrier Model Systems”, co-authored by Dr. Hickman and Dr. Shuler, for the 2018 SLAS Technology Authors Choice Award. This award reflecting the article’s high impact and visibility throughout the 2017 year.
Hesperos President Dr. Mike Shuler has won the 2018 Biotechnology and Bioengineering Gaden Award! The Gaden Award is named in honor of Elmer L. Gaden, Jr., the founding editor of Biotechnology & Bioengineering, and is given in recognition of a truly outstanding paper published in the journal during the last year. The paper selected for … Read more